Gene Reports, Journal Year: 2023, Volume and Issue: 31, P. 101763 - 101763
Published: March 11, 2023
Language: Английский
Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104620 - 104620
Published: Jan. 1, 2025
Language: Английский
Citations
1
Cellular & Molecular Biology Letters, Journal Year: 2023, Volume and Issue: 28(1)
Published: April 21, 2023
Abstract Hepatocellular carcinoma (HCC) is considered one of the greatest challenges to human life and most common form liver cancer. Treatment HCC depends on chemotherapy, radiotherapy, surgery, immunotherapy, all which have their own drawbacks, patients may develop resistance these therapies due aggressive behavior cells. New effective for can be developed by targeting molecular signaling pathways. The expression signal transducer activator transcription 3 (STAT3) in cancer cells changes, during progression, tends increase. After induction STAT3 growth factors cytokines, phosphorylated translocated nucleus regulate progression. concept current review revolves around phosphorylation status HCC, studies show that high progression HCC. This addresses function as an oncogenic factor able prevent apoptosis thus promote Moreover, regulates both survival- death-inducing autophagy promotes metastasis inducing epithelial–mesenchymal transition (EMT). In addition, upregulation associated with occurrence chemoresistance radioresistance Specifically, non-protein-coding transcripts inhibition antitumor agents affect tumor this review, topics are discussed detail provide further insight into role tumorigenesis, treatment resistance, pharmacological regulation Graphical
Language: Английский
Citations
20
Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 165, P. 115104 - 115104
Published: June 30, 2023
Hepatocellular carcinoma (HCC) is the second most lethal cancer and a leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) significantly improved prognosis HCC; however, therapeutic response remains unsatisfactory in substantial proportion patients or needs to be further responders. Herein, other methods immunotherapy, including vaccine-based adoptive cell therapy, cytokine delivery, kynurenine pathway inhibition, gene have been adopted clinical trials. Although results were not encouraging enough expedite their marketing. A major human genome transcribed into non-coding RNAs (ncRNAs). Preclinical studies extensively investigated roles ncRNAs different aspects HCC biology. cells reprogram expression pattern numerous decrease immunogenicity HCC, exhaust cytotoxic anti-cancer function CD8 + T cells, natural killer (NK) dendritic (DCs), M1 macrophages, promote immunosuppressive Reg M2 myeloid-derived suppressor (MDSCs). Mechanistically, recruit interact with immune thereby regulating checkpoints, functional receptors enzymes, inflammatory anti-inflammatory cytokines. Interestingly, prediction models based on tissue even serum levels could predict immunotherapy HCC. Moreover, markedly potentiated efficacy ICIs murine This review article first discusses recent advances then dissects involvement potential application
Language: Английский
Citations
20
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 13
Published: Jan. 4, 2023
Hepatocellular carcinoma (HCC) constitutes most primary liver cancers and is one of the lethal life-threatening malignancies globally. Unfortunately, a substantial proportion HCC patients are identified at an advanced stage that unavailable for curative surgery. Thus, palliative therapies represented by multi-tyrosine kinase inhibitors (TKIs) sorafenib remained front-line treatment over past decades. Recently, application immune checkpoint (ICIs), especially targeting PD-1/PD-L1/CTLA-4 axis, has achieved inspiring clinical breakthrough treating unresectable solid tumors. However, many with poor responses lead to limited benefits in applications, which quickly drawn researchers’ attention regulatory mechanisms checkpoints evasion. Evasion surveillance cancer attributed intricate reprogramming modulation tumor microenvironment. Currently, more studies have found epigenetic modifications, such as chromatin structure remodeling, DNA methylation, histone post-translational non-coding RNA levels, may contribute significantly remodeling microenvironment avoid clearance, affecting efficacy immunotherapy HCC. This review summarizes rapidly emerging progress epigenetic-related changes during resistance ICIs discusses underlying available surmounting resistance. Finally, we summarize advances combining immunotherapy, aiming promote formation combination therapy strategies.
Language: Английский
Citations
17
Cells, Journal Year: 2023, Volume and Issue: 12(6), P. 869 - 869
Published: March 10, 2023
Liver cancer is one of the most lethal cancers in world, mainly owing to lack effective means for early monitoring and treatment. Accordingly, there considerable research interest various clinically applicable methods addressing these unmet needs. At present, commonly used biomarker diagnosis liver alpha-fetoprotein (AFP), but AFP sensitive interference from other factors cannot really be as basis determining cancer. Treatment options addition surgery (resection, transplantation) include radiation therapy, chemotherapy, targeted therapy. However, even more expensive drug therapies have a limited impact on clinical outcome One big reasons rapid emergence resistance. Therefore, finding biomarkers diagnosis, an important focus current discussions how effectively adjust select strategies guidelines treatment patients. In this review, we bring thought process resistance problem faced by different strategies, approaching it perspective gene expression molecular biology possibility solutions.
Language: Английский
Citations
15
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Dec. 12, 2023
The application of immunotherapy in tumor, especially immune checkpoint inhibitors (ICIs), has played an important role the treatment advanced unresectable liver cancer. However, efficacy ICIs varies greatly among different patients, which aroused people’s attention to regulatory mechanism programmed death ligand-1 (PD-L1) escape PD-L1 is regulated by multiple levels and signaling pathways hepatocellular carcinoma (HCC), including gene variation, epigenetic inheritance, transcriptional regulation, post-transcriptional post-translational modification. More studies have also found that high expression may be main factor affecting what difference expressed types cells microenvironment HCC, type determines effect tumor remains unclear. Therefore, clarifying cancer can provide more basis for combined strategy. In addition its well-known plays a regulating cell proliferation promoting drug resistance cells, will reviewed this paper. addition, we summarized natural products drugs HCC.
Language: Английский
Citations
13
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9393 - 9393
Published: Aug. 29, 2024
Hepatocellular carcinoma (HCC) presents a significant global health burden, with alarming statistics revealing its rising incidence and high mortality rates. Despite advances in medical care, HCC treatment remains challenging due to late-stage diagnosis, limited effective therapeutic options, tumor heterogeneity, drug resistance. MicroRNAs (miRNAs) have attracted substantial attention as key regulators of pathogenesis. These small non-coding RNA molecules play pivotal roles modulating gene expression, implicated various cellular processes relevant cancer development. Understanding the intricate network miRNA-mediated molecular pathways is essential for unraveling complex mechanisms underlying hepatocarcinogenesis developing novel approaches. This manuscript aims provide comprehensive review recent experimental clinical discoveries regarding role miRNAs influencing hallmarks HCC, well their promising utility potential targets.
Language: Английский
Citations
5
Wiley Interdisciplinary Reviews - RNA, Journal Year: 2023, Volume and Issue: 15(1)
Published: Oct. 10, 2023
Non-coding RNAs (ncRNAs) have attracted extensive attention due to their vital roles in tumorigenesis and progression, especially the immunotherapy resistance. Tumor resistance is a crucial factor hindering efficacy of tumor treatments, which can be largely attributed immunosuppressive properties microenvironment. Current studies revealed that cancer-derived ncRNAs are involved formation microenvironment (TIME) through multiple ways. They not only promote expression immune checkpoint ligands (e.g., PD-L1, CD47, Gal-9, CD276) on cancer cell surfaces, but also enhance secretion cytokines TGF-β, IL-6, IL-10, VEGF, chemokines). Cancer-derived could transferred into surrounding immune-related cells extracellular vesicles, thereby inhibiting cytotoxicity CD8+ T NK cells, restraining DC-mediated antigen presentation, inducing phenotype transformation TAMs CAFs, enhancing functions Tregs MDSCs. Herein, we summarize regulating TIME further explore potential applications as prognostic biomarkers immunotherapeutic targets, will help us address TIME-mediated future. This article categorized under: RNA Disease Development > Regulatory RNAs/RNAi/Riboswitches RNAs.
Language: Английский
Citations
11
Journal of Chemotherapy, Journal Year: 2022, Volume and Issue: 35(5), P. 455 - 464
Published: Nov. 11, 2022
The incidence of hepatocellular carcinoma (HCC) is raised annually, which causes a great harm to people's health. This research aimed investigate the influence and mechanism methyltransferase-like 5 (METTL5) in HCC. According Cancer Genome Atlas (TCGA) database, METTL5 levels prognosis was analyzed Next, HCC tissues cells, expression examined via quantitative real-time polymerase chain reaction (qRT-PCR). Biological behaviors cells were assessed by Cell Counting Kit-8 (CCK-8), colony formation, transwell flow cytometry assays. Gene Set Enrichment Analysis (GSEA) applied predict related pathway. possible binding sites programmed cell death 1 ligand (PD-L1) myelocytomatosis viral oncogene (Myc) predicted JASPAR database. Western blot utilized test change PD-L1 Myc pathway proteins [cellular (c)-Myc, chaperonin containing TCP1 subunit 2 (CCT2) chromobox protein homolog 3 (CBX3)]. In increased. High associated with poor prognosis. Knockdown inhibited proliferation invasion, induced apoptosis reduced PD-L1, c-Myc, CCT2 CBX3. bind between promoter confirmed using Chip luciferase reporter Moreover, influences knockdown on biological reversed overexpression Myc. malignant behavior through inhibiting
Language: Английский
Citations
13
Cancers, Journal Year: 2023, Volume and Issue: 15(16), P. 4187 - 4187
Published: Aug. 21, 2023
Hepatocellular carcinoma (HCC) is a widely prevalent and malignantly progressive tumor. Most patients are typically diagnosed with HCC at an advanced stage, posing significant challenges in the execution of curative surgical interventions. Non-coding RNAs (ncRNAs) represent distinct category RNA molecules not directly involved protein synthesis. However, they possess remarkable ability to regulate gene expression, thereby exerting regulatory control over cellular processes. Notably, ncRNAs have been implicated modulation programmed cell death (PCD), crucial mechanism that various therapeutic agents target fight against HCC. This review summarizes clinical significance ncRNA regulation PCD HCC, including patient diagnosis, prognosis, drug resistance, side effects. The aim this study provide new insights directions for diagnosis treatment strategies
Language: Английский
Citations
7